Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""ErbB Receptors"" wg kryterium: Temat


Tytuł :
Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer.
Autorzy :
Kimura M; Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan .
Usami E; Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
Yoshimura T; Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Dec; Vol. 40 (12), pp. 7135-7140.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Colorectal Neoplasms/*drug therapy
ErbB Receptors/*therapeutic use
Hypercalciuria/*drug therapy
Nephrocalcinosis/*drug therapy
Renal Tubular Transport, Inborn Errors/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/pharmacology ; Colorectal Neoplasms/mortality ; ErbB Receptors/pharmacology ; Female ; Humans ; Hypercalciuria/etiology ; Male ; Middle Aged ; Nephrocalcinosis/etiology ; Renal Tubular Transport, Inborn Errors/etiology ; Retrospective Studies ; Survival Analysis
SCR Disease Name :
Hypomagnesemia primary
Czasopismo naukowe
Tytuł :
Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?
Autorzy :
Park S; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: .
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2020 Nov; Vol. 31 (11), pp. 1582. Date of Electronic Publication: 2020 Sep 02.
Typ publikacji :
Letter; Comment
MeSH Terms :
ErbB Receptors*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Acrylamides ; Aniline Compounds ; Central Nervous System ; Humans ; Mutation ; Protein Kinase Inhibitors/therapeutic use
Opinia redakcyjna
Tytuł :
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Autorzy :
Remon J; Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain. Electronic address: .
Hendriks LEL; Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands.
Cardona AF; Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia; Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia; Clinical Research and Biology Systems Department, Universidad el Bosque, Bogotá, Colombia.
Besse B; Gustave Roussy, Department of Cancer Medicine, Villejuif, France; Université Paris-Saclay, Orsay, France.
Pokaż więcej
Źródło :
Cancer treatment reviews [Cancer Treat Rev] 2020 Nov; Vol. 90, pp. 102105. Date of Electronic Publication: 2020 Sep 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Exons*
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
ErbB Receptors/*genetics
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/enzymology ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; ErbB Receptors/antagonists & inhibitors ; Genes, erbB-1 ; Humans ; Lung Neoplasms/enzymology ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Loss of p120ctn causes EGFR-targeted therapy resistance and failure.
Autorzy :
Landmesser ME; Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States of America.
Raup-Konsavage WM; Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States of America.
Lehman HL; Department of Biology, Millersville University, Millersville, Pennsylvania, United States of America.
Stairs DB; Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Oct 28; Vol. 15 (10), pp. e0241299. Date of Electronic Publication: 2020 Oct 28 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Resistance, Neoplasm*
Molecular Targeted Therapy*
Catenins/*deficiency
ErbB Receptors/*metabolism
Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Apoptosis/drug effects ; Catenins/metabolism ; Cell Line, Tumor ; Cetuximab/pharmacology ; Down-Regulation/drug effects ; ErbB Receptors/antagonists & inhibitors ; Erlotinib Hydrochloride/pharmacology ; Esophagus/pathology ; Gefitinib/pharmacology ; Humans ; Keratinocytes/drug effects ; Keratinocytes/metabolism ; NF-kappa B/metabolism ; Protein Kinase Inhibitors/pharmacology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans.
Autorzy :
van der Hoeven D; Department of Diagnostic and Biomedical Sciences, School of Dentistry, University of Texas Health Science Center; Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center.
Truong TNL; Department of Diagnostic and Biomedical Sciences, School of Dentistry, University of Texas Health Science Center.
Naji A; Department of Diagnostic and Biomedical Sciences, School of Dentistry, University of Texas Health Science Center.
Thapa S; Department of Diagnostic and Biomedical Sciences, School of Dentistry, University of Texas Health Science Center.
Hancock JF; Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center.
van der Hoeven R; Department of Diagnostic and Biomedical Sciences, School of Dentistry, University of Texas Health Science Center; .
Pokaż więcej
Źródło :
Journal of visualized experiments : JoVE [J Vis Exp] 2020 Oct 05 (164). Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Video-Audio Media
MeSH Terms :
Caenorhabditis elegans*
Drug Evaluation, Preclinical/*methods
ErbB Receptors/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
ras Proteins/*antagonists & inhibitors
Animals ; Cell Membrane/drug effects ; Cell Membrane/metabolism ; ErbB Receptors/metabolism ; Female ; Humans ; Phenotype ; Signal Transduction/drug effects ; ras Proteins/metabolism
Czasopismo naukowe
Tytuł :
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
Autorzy :
Dormieux A; Imaging Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Mezquita L; Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Cournede PH; MICS laboratory, CentraleSupélec, Université Paris-Saclay, Gif-sur-Yvette, France.
Remon J; Medical Oncology Department, Centro Integral Oncología Clara Campal Bacelona, HM-Delfos, Barcelona, Spain.
Tazdait M; Imaging Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Lacroix L; Molecular Biology Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Rouleau E; Molecular Biology Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Adam J; Pathology Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Bluthgen MV; Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Facchinetti F; Research Department (U981), Gustave Roussy Cancer Campus, Université Paris-Saclay, F-94805, Villejuif, France.
Tselikas L; Imaging Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Aboubakar F; Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Naltet C; Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Lavaud P; Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Gazzah A; Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Le Pechoux C; Radiation Therapy Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Lassau N; Imaging Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.; IR4M, UMR 8081, CNRS, Université Paris-Saclay, F-91400, Orsay, France.
Balleyguier C; Imaging Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.; IR4M, UMR 8081, CNRS, Université Paris-Saclay, F-91400, Orsay, France.
Planchard D; Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Besse B; Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Caramella C; Imaging Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France. .; IR4M, UMR 8081, CNRS, Université Paris-Saclay, F-91400, Orsay, France. .; Radiology Department, Gustave Roussy, 114 Rue Édouard-Vaillant, 94805, Villejuif Cedex, France. .
Pokaż więcej
Źródło :
European radiology [Eur Radiol] 2020 Sep; Vol. 30 (9), pp. 5021-5028. Date of Electronic Publication: 2020 Apr 23.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Neoplasm Staging*
Bone Neoplasms/*secondary
Carcinoma, Non-Small-Cell Lung/*diagnosis
DNA, Neoplasm/*genetics
ErbB Receptors/*genetics
Lung Neoplasms/*diagnosis
Adult ; Aged ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Bone Neoplasms/diagnosis ; Bone Neoplasms/genetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/secondary ; ErbB Receptors/metabolism ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3.
Autorzy :
Yan M; Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Chen J; Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Jiang H; Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Xie Y; Clinical Research Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Li C; Clinical Research Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Chen L; Clinical Research Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Yang B; Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Cao J; Clinical Research Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Aug 03; Vol. 15 (8), pp. e0237098. Date of Electronic Publication: 2020 Aug 03 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Caspase 3/*metabolism
ErbB Receptors/*genetics
MicroRNAs/*genetics
Neoplasms, Experimental/*therapy
RNAi Therapeutics/*methods
Adenoviridae/genetics ; Animals ; Antineoplastic Combined Chemotherapy Protocols ; Apoptosis ; Caspase 3/genetics ; Cell Line, Tumor ; Cell Proliferation ; Cetuximab/administration & dosage ; Cetuximab/therapeutic use ; Cisplatin/administration & dosage ; Cisplatin/therapeutic use ; ErbB Receptors/metabolism ; HEK293 Cells ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; MicroRNAs/metabolism ; Mitogen-Activated Protein Kinase 1/metabolism ; Mitogen-Activated Protein Kinase 3/metabolism ; Neoplasms, Experimental/drug therapy ; Proto-Oncogene Proteins c-akt/metabolism
Czasopismo naukowe
Tytuł :
Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Autorzy :
Liu Y; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.; Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Sciences, Changchun, China.; Zhengzhou Institute of Engineering and Technology Affiliated with SIBET, Zhengzhou, China.
Zhou Y; Soochow University, Suzhou, China.
Huang KH; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.
Fang X; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.
Li Y; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.
Wang F; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.; Zhengzhou Institute of Engineering and Technology Affiliated with SIBET, Zhengzhou, China.
An L; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.; Zhengzhou Institute of Engineering and Technology Affiliated with SIBET, Zhengzhou, China.
Chen Q; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.
Zhang Y; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.
Shi A; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.; Zhengzhou Institute of Engineering and Technology Affiliated with SIBET, Zhengzhou, China.
Yu S; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.; Xuzhou Medical University, Xuzhou, China.
Zhang J; The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.; Xuzhou Medical University, Xuzhou, China.; Tianjin Guokeyigong Science and Technology Development Company Limited, Tianjin, China.; Zhengzhou Institute of Engineering and Technology Affiliated with SIBET, Zhengzhou, China.
Pokaż więcej
Źródło :
Cell proliferation [Cell Prolif] 2020 Aug; Vol. 53 (8), pp. e12858. Date of Electronic Publication: 2020 Jun 27.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
ErbB Receptors/*metabolism
Killer Cells, Natural/*immunology
Triple Negative Breast Neoplasms/*metabolism
Animals ; Antineoplastic Agents/metabolism ; Cell Line, Tumor ; Disease Models, Animal ; Epidermal Growth Factor/metabolism ; ErbB Receptors/immunology ; Humans ; Mice ; Receptors, Chimeric Antigen/immunology ; Triple Negative Breast Neoplasms/drug therapy ; Xenograft Model Antitumor Assays/methods
Czasopismo naukowe
Tytuł :
Molecular characterization and function of EGFR during viral infectionprocess in Mandarin fishSiniperca chuatsi.
Autorzy :
Niu Y; Pearl River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of Fishery Drug Development, Ministry of Agriculture and Rural Affairs, Key Laboratory of Aquatic Animal Immune Technology, Guangdong Provinces, Guangzhou, 510380, China.
Fu X; Pearl River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of Fishery Drug Development, Ministry of Agriculture and Rural Affairs, Key Laboratory of Aquatic Animal Immune Technology, Guangdong Provinces, Guangzhou, 510380, China.
Liu L; Pearl River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of Fishery Drug Development, Ministry of Agriculture and Rural Affairs, Key Laboratory of Aquatic Animal Immune Technology, Guangdong Provinces, Guangzhou, 510380, China.
Lin Q; Pearl River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of Fishery Drug Development, Ministry of Agriculture and Rural Affairs, Key Laboratory of Aquatic Animal Immune Technology, Guangdong Provinces, Guangzhou, 510380, China.
Liang H; Pearl River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of Fishery Drug Development, Ministry of Agriculture and Rural Affairs, Key Laboratory of Aquatic Animal Immune Technology, Guangdong Provinces, Guangzhou, 510380, China.
Huang Z; Pearl River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of Fishery Drug Development, Ministry of Agriculture and Rural Affairs, Key Laboratory of Aquatic Animal Immune Technology, Guangdong Provinces, Guangzhou, 510380, China.
Li N; Pearl River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Key Laboratory of Fishery Drug Development, Ministry of Agriculture and Rural Affairs, Key Laboratory of Aquatic Animal Immune Technology, Guangdong Provinces, Guangzhou, 510380, China. Electronic address: .
Pokaż więcej
Źródło :
Fish & shellfish immunology [Fish Shellfish Immunol] 2020 Jul; Vol. 102, pp. 211-217. Date of Electronic Publication: 2020 Apr 13.
Typ publikacji :
Journal Article
MeSH Terms :
ErbB Receptors/*genetics
ErbB Receptors/*immunology
Fish Diseases/*immunology
Gene Expression Regulation/*immunology
Immunity, Innate/*genetics
Perciformes/*genetics
Perciformes/*immunology
Animals ; ErbB Receptors/chemistry ; Fish Proteins/chemistry ; Fish Proteins/genetics ; Fish Proteins/immunology ; Gene Expression Profiling/veterinary ; Phylogeny ; Sequence Alignment/veterinary ; Sequence Analysis, DNA/veterinary
Czasopismo naukowe
Tytuł :
GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody.
Autorzy :
Gedeon PC; Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States of America.; Department of Biomedical Engineering, Duke University, Durham, NC, United States of America.; The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States of America.
Streicker MA; Integrated Laboratory Systems, Inc., Research Triangle Park, NC, United States of America.
Schaller TH; Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States of America.; The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States of America.; Department of Pathology, Duke University Medical Center, Durham, NC, United States of America.
Archer GE; Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States of America.; The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States of America.
Jokinen MP; Integrated Laboratory Systems, Inc., Research Triangle Park, NC, United States of America.
Sampson JH; Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States of America.; Department of Biomedical Engineering, Duke University, Durham, NC, United States of America.; The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States of America.; Department of Pathology, Duke University Medical Center, Durham, NC, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jul 31; Vol. 15 (7), pp. e0236374. Date of Electronic Publication: 2020 Jul 31 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antibodies, Bispecific/*pharmacology
CD3 Complex/*immunology
ErbB Receptors/*immunology
Glioma/*immunology
Animals ; Antibodies, Bispecific/immunology ; Body Weight/drug effects ; Body Weight/immunology ; CD3 Complex/pharmacology ; Disease Models, Animal ; ErbB Receptors/pharmacology ; Female ; Glioma/pathology ; Glioma/therapy ; Humans ; Immunotherapy/adverse effects ; Male ; Mice ; Single-Chain Antibodies/immunology ; Single-Chain Antibodies/pharmacology ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology
Czasopismo naukowe
Tytuł :
How good are comparative models in the understanding of protein dynamics?
Autorzy :
Yazhini A; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, Karnataka, India.
Srinivasan N; Molecular Biophysics Unit, Indian Institute of Science, Bangalore, Karnataka, India.
Pokaż więcej
Źródło :
Proteins [Proteins] 2020 Jul; Vol. 88 (7), pp. 874-888. Date of Electronic Publication: 2020 Feb 11.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Dynamics Simulation*
ErbB Receptors/*chemistry
Ribonuclease, Pancreatic/*chemistry
Ribonucleases/*chemistry
Amino Acid Sequence ; Binding Sites ; Crystallography, X-Ray ; ErbB Receptors/metabolism ; Humans ; Mutation ; Protein Binding ; Protein Conformation, alpha-Helical ; Protein Conformation, beta-Strand ; Protein Interaction Domains and Motifs ; Ribonuclease, Pancreatic/metabolism ; Ribonucleases/metabolism ; Structural Homology, Protein ; Thermodynamics
Czasopismo naukowe
Tytuł :
New therapeutic approaches to overcoming resistant EGFR exon 20 alterations.
Autorzy :
Li AM; University of California San Diego School of Medicine, 9500 Gilman Dr, La Jolla, CA, 92093, USA. Electronic address: .
Boichard A; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. Electronic address: .
Felip E; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119, 129, 08035, Barcelona, Spain. Electronic address: .
Kurzrock R; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA, 92093, USA. Electronic address: .
Pokaż więcej
Źródło :
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2020 Jul; Vol. 151, pp. 102990. Date of Electronic Publication: 2020 May 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Resistance, Neoplasm*
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
ErbB Receptors/*genetics
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Cetuximab/therapeutic use ; ErbB Receptors/chemistry ; Exons ; Humans ; Mutation ; Organophosphorus Compounds/therapeutic use ; Protein Kinase Inhibitors ; Pyrimidines/therapeutic use
Czasopismo naukowe
Tytuł :
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.
Autorzy :
Schmitt J; Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada.
Huang S; Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada.
Goodfellow E; Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada.
Williams C; Scientific Support, Chemical Computing Group Inc., Montreal, QC H3A 2R7, Canada.
Jean-Claude BJ; Cancer Drug Research Laboratory, Department of Medicine, The Research Institute of the McGill University Health Center/Glen Hospital, Montreal, QC H4A 3J1, Canada.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Jun 11; Vol. 63 (11), pp. 5752-5762. Date of Electronic Publication: 2020 Jun 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Damage*/drug effects
Drug Design*
ErbB Receptors/*antagonists & inhibitors
Poly(ADP-ribose) Polymerase Inhibitors/*chemical synthesis
Poly(ADP-ribose) Polymerases/*chemistry
Cell Line, Tumor ; Down-Regulation/drug effects ; ErbB Receptors/metabolism ; Humans ; Male ; Poly(ADP-ribose) Polymerase Inhibitors/metabolism ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Poly(ADP-ribose) Polymerases/metabolism ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
Autorzy :
Shi Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, People's Republic of China. Electronic address: .
Zhang S; Department of Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Oncology Institute, Beijing, People's Republic of China.
Hu X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, People's Republic of China.
Feng J; Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, People's Republic of China.
Ma Z; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Zhou J; Department of Respiratory Medicine, the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Yang N; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
Wu L; Department of Gastroenterology, Hunan Cancer Hospital, Changsha, People's Republic of China.
Liao W; Department of Medical Oncology, Nanfang Hospital, Nanfang Medical University, Guangzhou, People's Republic of China.
Zhong D; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Han X; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, People's Republic of China.
Wang Z; Department of Thoracic Oncology, Unit I, Peking University Cancer Hospital, Beijing, People's Republic of China.
Zhang X; Department of Medical Oncology, Nantong Cancer Hospital, Nantong, People's Republic of China.
Qin S; Department of Medical Oncology, PLA Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
Ying K; Department of Respiratory Medicine, Sir Run Shaw Hospital, Affiliated With Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Feng J; Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, People's Republic of China.
Fang J; Department of Thoracic Oncology, Unit II, Peking University Cancer Hospital, Beijing, People's Republic of China.
Liu L; Department of Thoracic Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Jiang Y; Clinical Affairs and Regulatory Department, Shanghai Allist Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2020 Jun; Vol. 15 (6), pp. 1015-1026. Date of Electronic Publication: 2020 Jan 30.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
ErbB Receptors*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Indoles ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Pyridines ; Pyrimidines
Czasopismo naukowe
Tytuł :
Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis.
Autorzy :
Li ZX; Department of Oncology, General Hospital of PLA Rocket Force, Beijing, 100088, China.
Zhao W; Department of Oncology, General Hospital of PLA Rocket Force, Beijing, 100088, China.
Sun Q; Department of General Surgery, General Hospital of PLA Rocket Force, No. 16 Xinjiekouwai Street, Xicheng District, Beijing, 100088, China.
Tang MS; Department of General Surgery, General Hospital of PLA Rocket Force, No. 16 Xinjiekouwai Street, Xicheng District, Beijing, 100088, China.
Xia QJ; Department of General Surgery, General Hospital of PLA Rocket Force, No. 16 Xinjiekouwai Street, Xicheng District, Beijing, 100088, China. .
Dong MS; Department of General Surgery, General Hospital of PLA Rocket Force, No. 16 Xinjiekouwai Street, Xicheng District, Beijing, 100088, China. .
Pokaż więcej
Źródło :
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2020 Jun; Vol. 22 (6), pp. 892-899. Date of Electronic Publication: 2019 Sep 19.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Acrylamides/*therapeutic use
Aniline Compounds/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
ErbB Receptors/*antagonists & inhibitors
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Mutation ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
Autorzy :
Cortellini A; Medical Oncology Unit, St. Salvatore Hospital, Via Vetoio, 67100, L'Aquila, Italy. .; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. .
Leonetti A; Medical Oncology, University Hospital of Parma, Parma, Italy.
Catino A; Thoracic Oncology Unit, Clinical Cancer Centre 'Giovanni Paolo II', Bari, Italy.
Pizzutillo P; Thoracic Oncology Unit, Clinical Cancer Centre 'Giovanni Paolo II', Bari, Italy.
Ricciuti B; Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy.
De Giglio A; Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy.
Chiari R; Medical Oncology, Ospedali Riuniti Padova Sud 'Madre Teresa Di Calcutta', Monselice, Italy.
Bordi P; Medical Oncology, University Hospital of Parma, Parma, Italy.
Santini D; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Giusti R; Medical Oncology, Sant'Andrea Hospital, Rome, Italy.
De Tursi M; Department of Medical, Oral and Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Italy.
Brocco D; Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy.
Zoratto F; Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy.
Rastelli F; Medical Oncology, Fermo Area Vasta 4, Fermo, Italy.
Citarella F; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Russano M; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Filetti M; Medical Oncology, Sant'Andrea Hospital, Rome, Italy.
Marchetti P; Medical Oncology, Sant'Andrea Hospital, Rome, Italy.; Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Berardi R; Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy.
Torniai M; Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy.
Cortinovis D; Medical Oncology, Ospedale San Gerardo, Monza, Italy.
Sala E; Medical Oncology, Ospedale San Gerardo, Monza, Italy.
Maggioni C; Medical Oncology, Ospedale San Gerardo, Monza, Italy.
Follador A; Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine, Italy.
Macerelli M; Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine, Italy.
Nigro O; Medical Oncology, ASST-Sette Laghi, Varese, Italy.
Tuzi A; Medical Oncology, ASST-Sette Laghi, Varese, Italy.
Iacono D; Pulmonary Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy.
Migliorino MR; Pulmonary Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy.
Banna G; Medical Oncology Unit, Cannizzaro Hospital, Catania, Italy.
Porzio G; Medical Oncology Unit, St. Salvatore Hospital, Via Vetoio, 67100, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Cannita K; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Ferrara MG; Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
Bria E; Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
Galetta D; Thoracic Oncology Unit, Clinical Cancer Centre 'Giovanni Paolo II', Bari, Italy.
Ficorella C; Medical Oncology Unit, St. Salvatore Hospital, Via Vetoio, 67100, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Tiseo M; Medical Oncology, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy.
Pokaż więcej
Źródło :
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2020 Jun; Vol. 22 (6), pp. 844-851. Date of Electronic Publication: 2019 Aug 07.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Acrylamides/*therapeutic use
Aniline Compounds/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
ErbB Receptors/*genetics
Lung Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Combined Modality Therapy ; Disease Progression ; ErbB Receptors/antagonists & inhibitors ; Female ; Health Knowledge, Attitudes, Practice ; Humans ; Italy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Lung Neoplasms/surgery ; Male ; Middle Aged ; Mutation ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
Autorzy :
Wang G; Department of Medical Oncology, Anhui, The First Affiliated Hospital of University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, 230001, People's Republic of China.
He Y; Department of Medical Oncology, Anhui, The First Affiliated Hospital of University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, 230001, People's Republic of China.
Sun Y; Department of Medical Oncology, Anhui, The First Affiliated Hospital of University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, 230001, People's Republic of China.
Wang W; Department of Medical Oncology, Anhui, The First Affiliated Hospital of University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, 230001, People's Republic of China.
Qian X; Department of Medical Oncology, Anhui, The First Affiliated Hospital of University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, 230001, People's Republic of China.
Yu X; Merck Serono Co. Ltd., Pudong District, Shanghai, People's Republic of China.
Pan Y; Department of Medical Oncology, Anhui, The First Affiliated Hospital of University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei, 230001, People's Republic of China. .
Pokaż więcej
Źródło :
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2020 Jun; Vol. 22 (6), pp. 813-822. Date of Electronic Publication: 2019 Oct 05.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Colorectal Neoplasms/*drug therapy
Drug Resistance, Neoplasm/*genetics
ErbB Receptors/*antagonists & inhibitors
Receptor, ErbB-2/*genetics
Biomarkers, Tumor/genetics ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; ErbB Receptors/therapeutic use ; Humans ; Mutation ; Prevalence ; Prognosis
Czasopismo naukowe
Tytuł :
The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer.
Autorzy :
Li GC; Division of Digestive Surgery, Hospital of Digestive Diseases, Xi'an International Medical Centre.
Jia XC; Division of Pathology.
Zhao QC; Division of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Zhang HW; Division of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Yang P; Division of Digestive Surgery, Hospital of Digestive Diseases, Xi'an International Medical Centre.
Xu LL; Division of Digestive Surgery, Hospital of Digestive Diseases, Xi'an International Medical Centre.
Pang FN; Division of Digestive Surgery, Hospital of Digestive Diseases, Xi'an International Medical Centre.
Sun JB; Division of Digestive Surgery, Hospital of Digestive Diseases, Xi'an International Medical Centre.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 May 22; Vol. 99 (21), pp. e20460.
Typ publikacji :
Journal Article
MeSH Terms :
ErbB Receptors/*analysis
Gastrectomy/*statistics & numerical data
Peptide Fragments/*analysis
Stomach Neoplasms/*mortality
Adult ; Aged ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/blood ; China/epidemiology ; ErbB Receptors/blood ; Female ; Gastrectomy/methods ; Humans ; Male ; Middle Aged ; Peptide Fragments/blood ; Prospective Studies ; Retrospective Studies ; Stomach Neoplasms/blood ; Stomach Neoplasms/epidemiology ; Survival Analysis
Czasopismo naukowe
Tytuł :
Amphiregulin promotes cardiac fibrosis post myocardial infarction by inducing the endothelial-mesenchymal transition via the EGFR pathway in endothelial cells.
Autorzy :
Liu L; Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Song S; Department of Cardiology, Affiliated Xinhua Hospital, Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai, China.
Zhang YP; Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Wang D; Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Zhou Z; Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Chen Y; Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Jin X; Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Hu CF; Department of Ultrasound in Medicine, Minhang Hospital, Fudan University, Shanghai, China. Electronic address: .
Shen CX; Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. Electronic address: .
Pokaż więcej
Źródło :
Experimental cell research [Exp Cell Res] 2020 May 15; Vol. 390 (2), pp. 111950. Date of Electronic Publication: 2020 Mar 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Amphiregulin/*genetics
Endothelial Cells/*metabolism
Epithelial-Mesenchymal Transition/*genetics
ErbB Receptors/*genetics
Myocardial Infarction/*genetics
Myocardium/*metabolism
Actins/genetics ; Actins/metabolism ; Amphiregulin/metabolism ; Animals ; Cadherins/genetics ; Cadherins/metabolism ; Cell Survival ; Collagen Type I/genetics ; Collagen Type I/metabolism ; Collagen Type III ; Coronary Vessels/surgery ; Disease Models, Animal ; Endomyocardial Fibrosis ; Endothelial Cells/pathology ; ErbB Receptors/metabolism ; Gene Expression Regulation ; Human Umbilical Vein Endothelial Cells ; Humans ; Ligation ; Male ; Mice ; Mice, Inbred C57BL ; Myocardial Infarction/metabolism ; Myocardial Infarction/pathology ; Myocardium/pathology ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Signal Transduction ; Vimentin/genetics ; Vimentin/metabolism
Czasopismo naukowe
Tytuł :
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
Autorzy :
Yang JC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: .
Schuler M; West German Cancer Center, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
Popat S; Lung Unit, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom.
Miura S; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Heeke S; Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, University Hospital Federation OncoAge, Nice, France.
Park K; Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Märten A; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Kim ES; Department of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2020 May; Vol. 15 (5), pp. 803-815. Date of Electronic Publication: 2020 Jan 10.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
ErbB Receptors*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Afatinib/therapeutic use ; Humans ; Mutation ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies